Pier Capital’s Coherus Oncology CHRS Stock Holding History

Pier Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-343,308	Closed	-$7.59M	–	107
2019 Q2	$7.59M	Sell	343,308 -182,540	-35%	-$3.17M	1.17%	32
2019 Q1	$7.17M	Sell	525,848 -81,748	-13%	-$1.09M	1.11%	51
2018 Q4	$5.5M	Sell	607,596 -29,148	-5%	-$337K	1.09%	51
2018 Q3	$10.5M	Buy	636,744 +384,501	+152%	+$6.82M	1.33%	6
2018 Q2	$3.53M	Buy	+252,243	New	+$3.61M	0.49%	97

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Pier Capital's CHRS Position: Q3 2019 in Review

Pier Capital sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 343,308 shares — an estimated $7.59M sold.

Pier Capital first reported a position in CHRS in Q2 2018 and held it in 5 quarters. The position peaked at $10.5M in Q3 2018. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

Pier Capital reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
Pier Capital sold 343,308 Coherus Oncology shares in Q3 2019, an estimated $7.59M.
Pier Capital first reported a position in Coherus Oncology in Q2 2018 and held it in 5 quarters.
Pier Capital's Coherus Oncology position peaked at $10.5M in Q3 2018.
167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Pier Capital's 13F filing for Q3 2019, filed 13 Nov 2019.